Abbott India Ltd.

BSE: ABBOTINDIA500488ISIN INE358A01014

Healthcare
Pharmaceuticals
BSE 200

Share price

₹27,146.85+1,341.55 (+5.20%)

as of 4 Nov 2026

Prices adjusted for splits and bonuses; cash dividends excluded. Volume shows actual shares traded.

52W high: ₹30,598.00
52W low: ₹24,670.10
Off 52W high: -11.28%
1M return: +3.18%
3M return: -2.11%
6M return: +3.24%
1Y return: -7.56%
20D avg volume: 1,268
50 DMA: ₹26,151.85
200 DMA: ₹26,635.11

Key ratios Standalone

Market cap: ₹57,685 Cr
Current price: ₹27,146.85
52W high / low: ₹30,598.00 / ₹24,670.10
Face value: ₹10.00
P/E: 35.73
P/B: 16.38
EPS (TTM): ₹759.87
Book value / share: ₹1,657.32
ROE: 45.86%
ROCE: 41.90%
Operating margin: 32.96%
Net margin: 23.63%
Debt / equity: 0.00
Net debt: ₹-442.33 Cr
Interest cover: 84.20
Dividend yield: 2.42%
Dividend / share (TTM): ₹656.00
Payout: 86.33%
Cash conversion cycle: 10.7 days

Financials

Metric	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24	Q2 FY24
Income statement
	1,814	1,710	1,724	1,757	1,738	1,605	1,614	1,633	1,558	1,439	1,437	1,494
	75.37	75.59	69.76	69.95	72.84	76.02	71.75	60.48	67.33	81.15	55.61	55.51
	1,889	1,785	1,794	1,827	1,811	1,681	1,686	1,693	1,625	1,520	1,493	1,550
	1,317	1,254	1,285	1,281	1,318	1,198	1,198	1,214	1,188	1,130	1,071	1,134
	150.63	157.80	147.31	162.59	146.18	186.68	116.10	172.06	146.28	161.79	116.63	140.29
	812.06	809.54	752.58	733.32	868.79	787.36	749.19	738.49	781.30	747.24	668.35	639.61
	175.24	145.76	196.07	158.98	168.01	144.40	134.68	147.40	161.06	145.24	139.19	142.70
	5.91	6.14	5.48	7.55	5.82	3.92	2.26	2.50	2.75	2.81	3.17	3.13
	19.75	19.07	18.77	18.64	19.48	17.93	17.99	17.51	18.37	18.19	17.97	17.84
	184.35	177.86	155.69	159.15	182.63	175.69	150.81	144.55	159.18	157.96	133.47	156.21
	572.21	531.23	508.98	545.93	493.13	482.71	487.59	479.43	437.22	389.68	422.16	415.42
	0.00	0.00	0.00	0.00	0.00	0.00	—	—	—	—	—	—
	572.21	531.23	508.98	545.93	493.13	482.71	487.59	479.43	437.22	389.68	422.16	415.42
	143.69	136.30	133.02	130.66	127.27	115.67	126.81	120.82	109.21	102.62	111.18	102.48
	428.52	394.93	375.96	415.27	365.86	367.04	360.78	358.61	328.01	287.06	310.98	312.94
	201.66	185.85	176.92	195.42	172.17	172.72	169.78	168.76	154.36	135.09	146.34	147.27
Key metrics
	597.87	556.44	533.23	572.12	518.43	504.56	507.84	499.44	458.34	410.68	443.30	436.39
	33.00%	32.50%	30.90%	32.60%	29.80%	31.40%	31.50%	30.60%	29.40%	28.50%	30.80%	29.20%
	23.60%	23.10%	21.80%	23.60%	21.00%	22.90%	22.30%	22.00%	21.10%	20.00%	21.60%	20.90%
	—	10.70%	—	12.90%	—	10.80%	—	—	—	—	—	—
	4.30%	6.50%	6.80%	7.60%	11.60%	11.50%	12.30%	9.30%	—	—	—	—
	17.10%	7.60%	4.20%	15.80%	11.50%	27.90%	16.00%	14.60%	—	—	—	—

Metric	TTM	FY26	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17
Income statement
	7,004	6,929	6,409	5,849	5,349	4,919	4,310	4,093	3,679	3,307	2,939
	290.67	288.14	275.58	248.27	154.15	77.21	80.90	114.39	113.29	116.99	57.64
	7,295	7,217	6,685	6,097	5,503	4,996	4,391	4,208	3,792	3,424	2,996
	5,137	5,138	4,798	4,479	4,229	3,917	3,465	3,405	3,093	2,803	2,560
	618.33	613.88	621.12	565.67	558.61	495.46	454.32	451.76	406.40	295.72	315.94
	3,108	3,164	3,056	2,647	2,350	2,184	2,041	1,803	1,684	1,711	1,498
	676.05	668.82	587.54	576.58	563.59	579.46	492.65	476.11	435.58	393.69	345.27
	25.08	24.99	11.43	12.45	15.99	19.10	18.28	8.53	2.25	3.82	2.04
	76.23	75.96	71.80	71.17	69.97	66.10	58.13	59.61	16.92	16.19	16.43
	677.05	675.33	630.23	598.62	604.45	594.88	504.99	544.94	549.69	475.57	447.91
	2,158	2,079	1,887	1,618	1,274	1,080	925.95	802.69	698.85	621.48	436.49
	0.00	0.00	0.00	—	—	—	—	—	—	—	—
	2,158	2,079	1,887	1,618	1,274	1,080	925.95	802.69	698.85	621.48	436.49
	543.67	527.25	472.51	416.53	324.41	281.03	235.26	209.76	248.52	220.26	159.84
	1,615	1,552	1,414	1,201	949.41	798.70	690.69	592.93	450.33	401.22	276.65
	759.85	730.36	665.62	565.28	446.78	375.86	325.04	279.04	211.93	188.81	—
Key metrics
	2,260	2,180	1,970	1,701	1,360	1,165	1,002	870.83	718.02	641.49	454.96
	32.26%	31.50%	30.70%	29.10%	25.40%	23.70%	23.30%	21.30%	19.50%	19.40%	15.50%
	23.05%	22.40%	22.10%	20.50%	17.80%	16.20%	16.00%	14.50%	12.20%	12.10%	9.40%
	—	41.90%	42.10%	—	—	—	—	—	—	—	—
	6.29%	8.10%	9.60%	9.40%	8.70%	14.10%	5.30%	11.30%	11.20%	12.50%	—
	11.18%	9.70%	17.80%	26.50%	18.90%	15.60%	16.50%	31.70%	12.20%	45.00%	—
	—	1,278	959.24	—	—	—	—	—	—	—	—
	—	0.85	0.72	—	—	—	—	—	—	—	—
	—	0.00	0.00	—	—	—	—	—	—	—	—
	—	-442.33	-560.59	—	—	—	—	—	—	—	—
	—	10.7	11.7	—	—	—	—	—	—	—	—
Balance sheet
	—	6,502	5,917	—	—	—	—	—	—	—	—
	—	3,771	4,742	—	—	—	—	—	—	—	—
	—	442.33	560.59	—	—	—	—	—	—	—	—
	—	361.73	380.23	—	—	—	—	—	—	—	—
	—	947.26	882.04	—	—	—	—	—	—	—	—
	—	75.60	69.57	—	—	—	—	—	—	—	—
	—	327.54	329.52	—	—	—	—	—	—	—	—
	—	1,107	1,058	—	—	—	—	—	—	—	—
	—	1,477	1,407	—	—	—	—	—	—	—	—
	—	0.00	0.00	—	—	—	—	—	—	—	—
	—	0.00	0.00	—	—	—	—	—	—	—	—
	—	0.00	0.00	—	—	—	—	—	—	—	—
	—	4,774	4,233	—	—	—	—	—	—	—	—
Cash flow
	—	1,319	1,012	—	—	—	—	—	—	—	—
	—	-371.38	182.18	—	—	—	—	—	—	—	—
	—	-1,066	-925.17	—	—	—	—	—	—	—	—
	—	40.92	52.60	—	—	—	—	—	—	—	—

Compounded growth

Sales CAGR 3Y: +9.01%
Sales CAGR 5Y: +9.96%
Profit CAGR 3Y: +17.80%
Profit CAGR 5Y: +17.58%
Sales YoY (TTM): +6.29%
Profit YoY (TTM): +11.18%

Compounded from reported annual figures. We publish no share-price CAGR: our prices are as-traded, so one would be wrong across every split and bonus issue.

Shareholding as of 30 Sep 2026

Promoter holding: 74.98%

Quarter	September 2026	June 2026
Promoter %	74.98%	74.98%

Holder	Type	Holding	Previous	Change
ABBOTT CAPITAL INDIA LIMITED	Promoter	50.44%	50.44%	0.00%
ABBOTT HEALTHCARE PRODUCTS LIMITED	Promoter	17.62%	17.62%	0.00%
BRITISH COLLOIDS LIMITED	Promoter	6.92%	6.92%	0.00%
SBI NIFTY MIDCAP 150 INDEX FUND	Public	1.50%	—	—
NIPPON LIFE INDIA TRUSTEE LTD	Public	1.32%	1.07%	+0.25%
CANARA ROBECO MUTUAL FUND	Public	1.01%	1.07%	-0.06%

Public shareholders are disclosed individually only above 1%.

Peer comparison

Company	Mkt cap (₹ Cr)	Price (₹)	P/E	ROCE	Sales YoY	Profit YoY	1Y return
Sun Pharmaceutical Industries Ltd.	4,26,112	1,776.00	38.78	17.90%	+12.13% TTM	+4.79% TTM	+4.92%
Divi's Laboratories Ltd.	2,66,424	10,036.00	91.09	19.00%	+16.35% TTM	+26.84% TTM	+47.61%
Torrent Pharmaceuticals Ltd.	1,79,908	4,730.00	85.71	9.10%	+42.06% TTM	-1.92% TTM	+32.24%
Laurus Labs Limited	1,24,601	2,306.10	93.53	19.70%	+23.03% TTM	+95.38% TTM	+134.59%
Zydus Lifesciences Limited	1,18,703	1,190.00	25.85	19.20%	+21.11% TTM	-2.51% TTM	+22.32%
Dr. Reddy's Laboratories Ltd.	1,14,513	1,372.00	41.50	13.90%	-3.53% TTM	-51.90% TTM	+14.26%
Cipla Ltd.	1,13,110	1,400.10	39.63	14.90%	-0.74% TTM	-47.48% TTM	-6.88%
Mankind Pharma Limited	1,04,631	2,533.15	46.22	13.70%	+13.27% TTM	+27.60% TTM	+6.91%
Aurobindo Pharma Ltd.	97,878	1,701.10	26.38	13.60%	+9.09% TTM	+9.48% TTM	+47.79%
Lupin Ltd	92,145	2,015.00	17.65	28.40%	+24.22% TTM	+20.10% TTM	+0.84%
Glenmark Pharmaceuticals ltd	70,608	2,501.85	39.27	16.20%	+32.94% TTM	+138.48% TTM	+35.48%
Alkem Laboratories Limited	62,054	5,190.00	28.15	18.80%	+13.36% TTM	-5.52% TTM	-8.38%
Abbott India Ltd. S	57,685	27,146.85	35.73	41.90%	+6.29% TTM	+11.18% TTM	-7.56%
Biocon Ltd.	56,061	344.00	134.63	2.90%	+5.70% TTM	-55.37% TTM	-9.53%
Gland Pharma Limited	52,105	3,157.70	46.16	13.70%	+17.57% TTM	+46.55% TTM	+65.09%
Ipca Laboratories Ltd.	50,051	1,973.15	36.40	16.40%	+10.59% TTM	+67.91% TTM	+52.33%
GlaxoSmithkline Pharmaceuticals Ltd.	42,904	2,532.60	37.42	55.40%	+12.12% TTM	+20.03% TTM	-4.84%
Ajanta Pharma Ltd.	41,406	3,313.55	32.79	29.40%	+25.01% TTM	+29.70% TTM	+26.89%
Emcure Pharmaceuticals Limited	41,254	2,174.55	37.75	25.10%	+21.12% TTM	+33.34% TTM	+64.07%
J.B. Chemicals & Pharmaceuticals Lt	38,731	2,412.25	47.77	21.90%	+5.87% TTM	+7.56% TTM	+45.79%
Sai Life Sciences Limited	32,855	1,546.30	90.80	18.10%	—	—	+67.49%
PIRAMAL PHARMA LIMITED	31,659	237.80	-151.21	0.80%	+9.43% TTM	-781.93% TTM	+18.60%
ACUTAAS CHEMICALS LIMITED	30,928	3,777.65	70.51	27.70%	+45.18% TTM	+95.78% TTM	+106.30%
Wockhardt Ltd	30,869	1,899.80	76.22	6.40%	+25.70% TTM	+894.12% TTM	+39.18%
RUBICON RESEARCH LIMITED	28,416	1,716.55	98.59	24.30%	—	—	+164.06%

Filings & corporate actions

Recent announcements

Abbott India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/11/2026 ,inter alia, to consider and approve the Unaudited Financial Results ....26 Oct 2026 · Board Meeting / Board Meeting
Certificate under Regulation 74(5) of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018 for the quarter ended September 30, 2026.6 Oct 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Newspaper Advertisement - Special Window for Transfer and Dematerialization of Physical Securities.2 Oct 2026 · Company Update / Newspaper Publication
Closure of Trading Window for declaration of Unaudited Financial Results of the Company for the quarter ending September 30, 2026.28 Sep 2026 · Insider Trading / SAST / Closure of Trading Window
Resignation of Company Secretary and Compliance Officer of the Company.7 Sep 2026 · Company Update / Resignation of Company Secretary / Compliance Officer
Voting Results along with Consolidated Scrutinizer''s Report for the 82nd Annual General Meeting held on August 13, 2026.14 Aug 2026 · AGM/EGM / AGM
Newspaper Publication14 Aug 2026 · Company Update / Newspaper Publication
Proceedings of 82nd Annual General Meeting of the Company.13 Aug 2026 · AGM/EGM / AGM
Unaudited financial results for the quarter ended June 30, 2026.12 Aug 2026 · Result / Financial Results
Outcome of Board Meeting12 Aug 2026 · Board Meeting / Outcome of Board Meeting
Abbott India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/08/2026 ,inter alia, to consider and approve the Unaudited Financial Results ....4 Aug 2026 · Board Meeting / Board Meeting
Newspaper Advertisement - Special Window for Transfer and Dematerialization of Physical Securities4 Aug 2026 · Company Update / Newspaper Publication
Newspaper Advertisement for Eighty-second Annual General Meeting, E-voting facility and Dividend.20 Jul 2026 · Company Update / Newspaper Publication
Communication providing the weblink including path of Annual Report.20 Jul 2026 · Company Update / General
Submission of Business Responsibility and Sustainability Report for the Financial Year 2025-26.20 Jul 2026 · Others / Business Responsibility and Sustainability Reporting (BRSR)
Notice of the 82nd Annual General Meeting of the Company to be held on August 13, 2026.20 Jul 2026 · AGM/EGM / AGM
Annual Report for the financial year 2025-26.20 Jul 2026 · Others / Reg. 34 (1) Annual Report
Certificate under Regulation 74(5) of the Securities and Exchange Board of India (Depositories and Participants) Regulations , 2018 for the quarter ended June 30, 2026.9 Jul 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Closure of Trading Window.26 Jun 2026 · Insider Trading / SAST / Closure of Trading Window
Scrutinizer''s Report on Postal Ballot.17 Jun 2026 · AGM/EGM / Postal Ballot
Communication to Shareholders - Intimation about Tax Deduction at Source on Dividend.15 Jun 2026 · Company Update / General
Newspaper Advertisement - Special Window for Transfer and Dematerialization of Physical Securities.3 Jun 2026 · Company Update / Newspaper Publication
Newspaper Advertisement - Reminder to Shareholders - Unclaimed Dividends.27 May 2026 · Company Update / Newspaper Publication
Appointment of Senior Management Personnel.25 May 2026 · Company Update / Change in Management
Annual Secretarial Compliance Report under Regulation 24A(2) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.19 May 2026 · Company Update / Reg.24(A)-Annual Secretarial Compliance
Newspaper Publication.13 May 2026 · Company Update / Newspaper Publication
Newspaper publication.13 May 2026 · Company Update / Newspaper Publication
Postal Ballot Notice - Disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.13 May 2026 · AGM/EGM / Postal Ballot
Record Date for Dividend11 May 2026 · Corp. Action / Record Date
Audited Financial Results for the quarter and year ended March 31, 202611 May 2026 · Result / Financial Results
Outcome of Board Meeting11 May 2026 · Board Meeting / Outcome of Board Meeting
Abbott India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/05/2026 ,inter alia, to consider and approve Audited Financial Results of the ....30 Apr 2026 · Board Meeting / Board Meeting
Format of Initial Disclosure to be made by an entity identified as a Large Corporate. <table border=''1px''><tr> <td>Sr. No.</td> <td>Particulars</td> <td>Details</td> ....30 Apr 2026 · Others / Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
Intimation under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements), Regulations, 2015.22 Apr 2026 · Company Update / Change in Management
Outcome of Board Meeting.22 Apr 2026 · Others / Outcome without intimation
Certificate under Regulation 74(5) of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018 for the quarter ended March 31, 2026.8 Apr 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Newspaper Advertisement - Special Window for Transfer and Dematerialisation of Physical Securities.3 Apr 2026 · Company Update / Newspaper Publication
Closure of Trading Window24 Mar 2026 · Insider Trading / SAST / Closure of Trading Window
Abbott partners with Novo Nordisk India to launch Extensior, broadening access to Semaglutide (Ozempic) for advanced diabetes management.27 Feb 2026 · Company Update / Press Release / Media Release
Voting Results along with the Consolidated Scrutinizer''s Report.18 Feb 2026 · AGM/EGM / Postal Ballot

Corporate actions

Purpose	Ex date	Record date	Payment date
Final Dividend - Rs. - 525.0000	24 Jul 2026	24 Jul 2026	—
Special Dividend - Rs. - 131.0000	24 Jul 2026	24 Jul 2026	—
Final Dividend - Rs. - 475.0000	25 Jul 2025	25 Jul 2025	—
Final Dividend - Rs. - 410.0000	19 Jul 2024	19 Jul 2024	—

Board meetings

5 Nov 2026 Board Meeting - Financial Results
12 Aug 2026 Board Meeting - Financial Results